Breast cancer therapy and cardiovascular risk: focus on trastuzumab
Aamer Sandoo,1,2 George D Kitas,2 Amtul R Carmichael2 1School of Sport, Health and Exercise Sciences, Bangor University, Bangor, Wales, 2Dudley Group of Hospitals NHS Trust, Russells Hall Hospital, Dudley, UK Abstract: Breast cancer is the most common cancer in the UK. Advances in the methods of ea...
| Main Authors: | , , |
|---|---|
| Format: | Article |
| Language: | English |
| Published: |
Dove Medical Press
2015-04-01
|
| Series: | Vascular Health and Risk Management |
| Online Access: | http://www.dovepress.com/breast-cancer-therapy-and-cardiovascular-risk-focus-on-trastuzumab-peer-reviewed-article-VHRM |
| _version_ | 1818345863916814336 |
|---|---|
| author | Sandoo A Kitas GD Carmichael AR |
| author_facet | Sandoo A Kitas GD Carmichael AR |
| author_sort | Sandoo A |
| collection | DOAJ |
| description | Aamer Sandoo,1,2 George D Kitas,2 Amtul R Carmichael2 1School of Sport, Health and Exercise Sciences, Bangor University, Bangor, Wales, 2Dudley Group of Hospitals NHS Trust, Russells Hall Hospital, Dudley, UK Abstract: Breast cancer is the most common cancer in the UK. Advances in the methods of early diagnosis as well as newer and more effective treatments have led to improvements of disease-free and overall survival over the last decade. Almost one-third of breast cancers present with an aggressive form characterized by increased expression of human epidermal growth receptor 2 (HER2) proteins. A targeted treatment using monoclonal antibodies against HER2 expression such as trastuzumab has been shown to improve survival. Unfortunately, there is a degree of cardiotoxicity associated with these agents, as inhibition of HER2 pathways can also impair cardioprotective pathways. In the present review, we discuss the mechanisms by which trastuzumab might affect vascular homeostasis leading to endothelial dysfunction. We also provide suggestions for future research examining the effects of trastuzumab on the vasculature in breast cancer. Keywords: endothelial dysfunction, microvasculature, macrovasculature, congestive heart failure |
| first_indexed | 2024-12-13T17:09:08Z |
| format | Article |
| id | doaj.art-92394636219b4479970ae38ccc927e48 |
| institution | Directory Open Access Journal |
| issn | 1178-2048 |
| language | English |
| last_indexed | 2024-12-13T17:09:08Z |
| publishDate | 2015-04-01 |
| publisher | Dove Medical Press |
| record_format | Article |
| series | Vascular Health and Risk Management |
| spelling | doaj.art-92394636219b4479970ae38ccc927e482022-12-21T23:37:36ZengDove Medical PressVascular Health and Risk Management1178-20482015-04-012015default22322821195Breast cancer therapy and cardiovascular risk: focus on trastuzumabSandoo AKitas GDCarmichael ARAamer Sandoo,1,2 George D Kitas,2 Amtul R Carmichael2 1School of Sport, Health and Exercise Sciences, Bangor University, Bangor, Wales, 2Dudley Group of Hospitals NHS Trust, Russells Hall Hospital, Dudley, UK Abstract: Breast cancer is the most common cancer in the UK. Advances in the methods of early diagnosis as well as newer and more effective treatments have led to improvements of disease-free and overall survival over the last decade. Almost one-third of breast cancers present with an aggressive form characterized by increased expression of human epidermal growth receptor 2 (HER2) proteins. A targeted treatment using monoclonal antibodies against HER2 expression such as trastuzumab has been shown to improve survival. Unfortunately, there is a degree of cardiotoxicity associated with these agents, as inhibition of HER2 pathways can also impair cardioprotective pathways. In the present review, we discuss the mechanisms by which trastuzumab might affect vascular homeostasis leading to endothelial dysfunction. We also provide suggestions for future research examining the effects of trastuzumab on the vasculature in breast cancer. Keywords: endothelial dysfunction, microvasculature, macrovasculature, congestive heart failurehttp://www.dovepress.com/breast-cancer-therapy-and-cardiovascular-risk-focus-on-trastuzumab-peer-reviewed-article-VHRM |
| spellingShingle | Sandoo A Kitas GD Carmichael AR Breast cancer therapy and cardiovascular risk: focus on trastuzumab Vascular Health and Risk Management |
| title | Breast cancer therapy and cardiovascular risk: focus on trastuzumab |
| title_full | Breast cancer therapy and cardiovascular risk: focus on trastuzumab |
| title_fullStr | Breast cancer therapy and cardiovascular risk: focus on trastuzumab |
| title_full_unstemmed | Breast cancer therapy and cardiovascular risk: focus on trastuzumab |
| title_short | Breast cancer therapy and cardiovascular risk: focus on trastuzumab |
| title_sort | breast cancer therapy and cardiovascular risk focus on trastuzumab |
| url | http://www.dovepress.com/breast-cancer-therapy-and-cardiovascular-risk-focus-on-trastuzumab-peer-reviewed-article-VHRM |
| work_keys_str_mv | AT sandooa breastcancertherapyandcardiovascularriskfocusontrastuzumab AT kitasgd breastcancertherapyandcardiovascularriskfocusontrastuzumab AT carmichaelar breastcancertherapyandcardiovascularriskfocusontrastuzumab |